Kedrion Biopharma participates in ISTH 2025, taking place in Washington, D.C., from June 21 to 26. As a company committed to rare and ultra-rare diseases, Kedrion will bring to the global stage a strong scientific and educational presence, fostering knowledge exchange and meaningful dialogue within the bleeding disorders community.
Kedrion will host two scientific industry symposiums focused on the clinical understanding and management of two ultra rare diseases:
- On June 23rd “Understanding Hereditary Factor X Deficiency to optimize clinical management”
- On June 24th: “Plasminogen Deficiency: a rare multi-system disorder”
In addition, Kedrion supports the presentation of the poster titled “Challenging Established Paradigms: Lack of Correlation Between Factor X Levels and ISTH-BAT Scores in Factor x Deficiency”.
Moreover, the company is present with a booth that offers opportunities for networking and scientific exchange. An international delegation of leading Key Opinion Leaders (KOLs) will also take part in Kedrion’s activities, further contributing to the collaborative spirit of the congress.
Through our participation at ISTH 2025, we reaffirm our long-standing dedication to supporting clinicians, advancing research, and, above all, improving the lives of people affected by rare and ultra-rare bleeding disorders.